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Aim of database: To systematically monitor and improve the quality of treatment and care 
of patients with schizophrenia in Denmark. In addition, the database is accessible as a resource 
for research.
Study population: Patients diagnosed with schizophrenia and receiving mental health care 
in psychiatric hospitals or outpatient clinics. During the first year after the diagnosis, patients 
are classified as incident patients, and after this period as prevalent patients.
Main variables: The registry currently contains 21 clinical quality measures in relation to the 
following domains: diagnostic evaluation, antipsychotic treatment including adverse reactions, 
cardiovascular risk factors including laboratory values, family intervention, psychoeducation, 
postdischarge mental health care, assessment of suicide risk in relation to discharge, and assess-
ment of global functioning.
Descriptive data: The recorded data are available electronically for the reporting clinicians 
and responsible administrative personnel, and they are updated monthly. The registry publishes 
the national and regional results of all included quality measures in the annual audit reports. 
External researchers may obtain access to the data for use in specific research projects by apply-
ing to the steering committee.
Conclusion: The Danish Schizophrenia Registry represents a valuable source of informative 
data to monitor and improve the quality of care of patients with schizophrenia in Denmark. 
However, continuous resources and time devoted is necessary to maintain the integrity of the 
registry and the validity of the data.
Keywords: schizophrenia, national registry, quality of care, antipsychotic, adverse reactions, 
family intervention
Aim
To systematically monitor and annually audit the quality of the diagnostic evaluation, 
treatment, and care of patients with schizophrenia in Denmark. A further aim is to 
improve and facilitate progress and research in schizophrenia mental health care.
Study population
The Danish Schizophrenia Registry was founded in 2003. The registry comprises 
patients diagnosed with schizophrenia and receiving mental health care in psychiatric 
hospitals or outpatient clinics. All psychiatric treatment and care is public and financed 
by taxes. Data on both inpatient and outpatient care are collected and transferred from 
the National Patient Registry.1 In the year 2014, 14,324 patients were recorded in the 
 Danish Schizophrenia Registry via the National Patient Registry. During the first 
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year after the diagnosis, patients are classified as incident 
patients, and after this period reported as prevalent patients. 
General practitioners and  private  psychiatrists do not report 
to the registry due to national convention. If treated within 
these settings, the patients will, for the most part, present 
with only mild symptom severity or be in remission. Thus, 
patients with only mild symptom severity are not routinely 
recorded in the registry and thus are not available for quality 
monitoring or research.
Main clinical quality measures
introduction
The registry currently contains 21 clinical quality measures 
in relation to the following domains: diagnostic evaluation, 
antipsychotic treatment including adverse reactions, car-
diovascular risk factors including laboratory values, family 
intervention, psychoeducation, postdischarge mental health 
care, assessment of suicide risk in relation to discharge, 
and assessment of global functioning. The registry contains 
quality measures in relation to performance of a specific 
task or intervention (processes of care), as well as quality 
measures recorded and reported as numerical results (results 
of care). The core of the quality measures has been consistent 
since the registry was established in 2003, but new quality 
measures have been added by the steering committee of the 
registry. The quality measures have mainly been collected by 
manual registration into an electronic registry, but in recent 
years, several of the quality measures have been harvested 
from nationwide administrative registries to reduce the 
burden of registration. This includes information on antip-
sychotic treatment (from 2014), laboratory values (expected 
from 2015), and postdischarge psychiatric follow-up (from 
2012). However, due to administrative difficulties, the process 
of linkage between the relevant registries has not proven 
as efficient as expected, and a delay has been introduced 
regarding the electronic harvesting of some of these data.
The collection of data into the registry has changed 
within recent years. Before 2012, data were collected using 
a registration form with detailed written instructions. After 
January 1, 2012, data have been recorded in parallel with the 
collection of administrative data in the large national health 
care registries, which has required another set of registra-
tion procedures to be implemented. The change in record-
ing procedures was mainly driven by a wish to reduce the 
amount of double registration, but it has proven more difficult 
to implement than first expected and data quality dropped 
substantially with the change in registration. However, the 
registry is on its way to reestablish itself, reinforced by the 
updating of electronic medical records that will better sup-
port the recording of the defined quality measures. Overall, 
the experience from this registry shifting from manual to 
electronic data collection emphasizes the importance of user-
friendly interfaces with an easily available patient overview 
to facilitate electronic collection and recording of data.
For each quality measure, a desired absolute level (a stan-
dard) has been decided upon by the steering committee to 
reflect what is considered necessary to provide high quality 
service during diagnostic evaluation, treatment, and care 
of patients with schizophrenia. The quality measures with 
respective standards are listed in Table 1. The standard regard-
ing assessment of cognitive functioning does not reflect a 
consideration of the optimum level of quality of care. Instead, 
it reflects the role of the registry to support the development 
and improvement of schizophrenia treatment and care.
The steering committee is comprised of representatives 
from different geographic regions and relevant professional 
societies. Across the years, it has been the responsibility 
of the steering committee to select which quality measures 
to include. From the beginning, it was decided to keep the 
number of quality measures at a minimum to limit the burden 
of registration and to increase data completeness.
variables to assess the diagnostic evaluation
The quality measures related to the diagnostic evaluation 
comprise assessment of symptoms and signs performed by a 
board certified psychiatrist, assessment of psychopathology 
using a semistructured questionnaire (eg, the Present State 
Examination), assessment of cognitive functioning, assess-
ment of need of social support, and duration of untreated 
psychosis (DUP). Except for DUP, these quality measures 
are recorded and reported as processes of care, that is, 
indicating the proportion of patients having received these 
examinations as part of the diagnostic evaluation. As regards 
DUP, this variable is recorded as a categorical variable (DUP 
,3 months, DUP 3–6 months, DUP .6 months) to facilitate 
recording since clinicians have reported to the steering com-
mittee that they find it difficult to give an exact estimation of 
the onset of psychosis. The standard of this quality measure 
is DUP ,6 months, which was chosen pragmatically to indi-
cate a DUP markedly below what is usually seen in clinical 
trials (eg, mean length of DUP is reported to be 61.3 weeks 
in a recent review2). DUP has been considered important to 
evaluate by the steering committee since long DUP is associ-
ated with a poor general symptomatic and global outcome.2 
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Consequently, proper first episode treatment services should 
be available to reduce, in general, DUP in the society.
variables to assess the pharmacological 
treatment
The quality measures related to the pharmacological treat-
ment comprise treatment with antipsychotics, number of 
different antipsychotics used, and antipsychotic adverse reac-
tions. The latter includes neurological side effects, sleepiness 
and sedation, and sexual side effects.
variables to assess cardiovascular risk 
factors
The quality measures related to cardiovascular risk factors 
include body mass index, abdominal width, glycosylated 
hemoglobin (HbA1c), blood lipids, and blood pressure. The 
cardiovascular risk factors are recorded both as processes of 
care, that is, the fraction of schizophrenia patients who have 
these measures recorded, and as results of care, that is, the 
mean value of HbA1c among recorded patients or the  fraction 
of patients with increased levels. The evaluation of these 
quality measures as processes of care was driven by an aim to 
focus on the cardiovascular risk factors among patients with 
schizophrenia, because there is an urgent need to intervene 
against the excess cardiovascular mortality among patients 
with schizophrenia.3 With this focus, each recording inpatient 
or outpatient treatment unit can follow their own improve-
ments in obtaining and recording these measures. The task 
of improving the absolute values of the cardiovascular risk 
measurements is a much more difficult one, which includes 
implementation of various interventions (eg, increased physi-
cal activity and pharmacological interventions) in a model 
Table 1 Summary of the variables (including standards to define high quality treatment and care) in the Danish Schizophrenia Registry
Variable Reported as a process of  
care or as a result of care
Standard
Diagnostic evaluation
Assessment of symptoms and signs performed by a board  
certified psychiatrist
Process $90% (only recorded for incident patients)
Assessment of psychopathology using a semistructured 
questionnaire
Process $80% (only recorded for incident patients)
Assessment of cognitive functioning Process $50% (only recorded for incident patients)
Assessment of need of social support Process $80% (only recorded for incident patients)
DUP ,6 months Result $50% (only recorded for incident patients)
Antipsychotic treatment including adverse reactions
Treatment with antipsychotic(s) Process $90%
Treatment with antipsychotic polypharmacy Process ,20%
Adverse reactions: neurological Process ,10%
Adverse reactions: sleepiness and sedation Process ,15%
Adverse reactions: sexual Process ,10%
Cardiovascular risk factors including laboratory values
Body mass index Process (also recorded as result) $90%
Abdominal width Process (also recorded as result) $90%
HbA1c Process (also recorded as result) $90%
Blood lipids Process (also recorded as result) $90%
Blood pressure Process (also recorded as result) $90%
Psychosocial interventions
Family intervention Process $90% for incident patients  
$60% for prevalent patients
Psychoeducation Process $40% (only recorded for incident patients)
Postdischarge mental health care
Planned at discharge Process $90%
At least one ambulatory visit half a year after discharge Process $90%
Other
Assessment of suicide risk in relation to discharge Process $90%
GAF-F Result No standard, not for evaluation of the 
quality of care
Abbreviations: DUP, duration of untreated psychosis; GAF-F, global assessment of functioning; HbA1c, glycosylated hemoglobin.
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of shared care with general practice. Evaluation of these 
indicators as results of care will follow after the recording 
of the data has been optimized. Thus, the current focus is 
mainly on increasing the proportion of patients for whom 
the cardiovascular risk factors are  measured and recorded. 
When this is in place, the focus will shift to the absolute 
values of the cardiovascular risk factors and how these can 
be improved.
Other variables
The remainder of the quality measures encompasses family 
intervention, psychoeducation, postdischarge mental health 
care, assessment of suicide risk in relation to discharge, and 
assessment of global functioning using the Global Assess-
ment of Functioning Scale (split GAF-F). The GAF-F is 
recorded as the numerical value, but it is not reported along 
with the other quality measures and there is no fixed standard. 
It is primarily collected as an indicator of illness severity for 
use in registry-derived analyses and research.
validity
A study from 2012 investigated the validity of the quality 
of care data in the registry as compared with data extracted 
from the respective medical records.4 The results indicated 
substantial variability across the quality measures in the 
registry: sensitivity ranged from 11% to 96%, specificity 
ranged from 11% to 100%, and the ranges of the positive and 
negative predictive values were, respectively, 44%–100% and 
5%–100%. The authors noted that the results were limited 
by incomplete documentation of care in a high proportion 
of the examined medical records, which were considered the 
gold standard of recording.
Follow-up
The recorded data is available electronically for the  reporting 
clinicians and responsible administrative personnel, and it 
is updated monthly. The registry publishes the national and 
regional results of all included quality measures in the annual 
audit report. The steering committee meets once a year to 
audit the results of the preceding year and decides on the 
contents of the annual audit report with recommendations 
for future practice. The annual audit process is focused on 
evaluating whether the defined levels of high quality of care 
(the standards for each quality measure) are fulfilled, which 
is reported on a national level, on a regional level, on a 
hospital level, and on the level of individual departments of 
a certain size. At these meetings, it is decided whether any 
changes to the quality measures are warranted. Questions 
from clinicians or administrative staff in between the annual 
audits are discussed within a smaller group consisting of the 
national leadership and representatives from the Registry 
Support Centre of Clinical Quality and Health Informatics 
(West) and the Registry Support Centre of Epidemiology 
and Biostatistics (East).
Examples of research
Researchers may obtain access to the data in the registry for 
use in specific research projects by applying to the steering 
committee. Throughout the years, several studies have been 
published based on data from the Danish Schizophrenia 
Registry. It has been shown that the number of in-hospital 
processes of care received was associated with a lower risk 
of criminal behavior after discharge in patients with schizo-
phrenia.5 Another study documented an increase in systematic 
suicide risk assessment in relation to discharge after initiation 
of the registry.6 The Danish Schizophrenia Registry is the 
only Danish nationwide registry that contains a measure of 
functional ability (GAF-F), which is not the case for other 
Danish registries because they are structured around collec-
tion of data with an administrative purpose. Among others, 
an intervention study to reduce the frequency of antipsy-
chotic polypharmacy used GAF-F data from the registry to 
characterize the subjects in the intervention and control area 
regarding functional abilities.7 A recent study documented 
that quality of care improved with the implementation of the 
registry and the systematic monitoring program, but also that 
a high degree of variation between the hospitals remains.8
Administrative issues and funding
The registry is administered by the Danish Clinical Registries 
(RKKP), and the registry is managed by regional support 
centers specialized in epidemiology and biostatistics.
The registry is publicly funded by the RKKP for 3-year 
periods, which have been successively extended since the 
foundation of the registry in 2003.
Conclusion
The Danish Schizophrenia Registry represents an  important 
source for improving psychiatric care for patients with 
schizophrenia. The value of the registry lies in the collection 
of clinical data that are not otherwise available.  Furthermore, 
the registry provides an essential source of data for research 
purposes, in particular when linking with other central 
national registries. The collection of data regarding cardio-
vascular risk factors will eventually be a valuable source 
for further examinations of the link between metabolic 
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side effects and the excess mortality among schizophrenia 
patients.
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